Interestingly, the combination of both therapies synergistically reduced tumor growth and significantly (p value=0.0171) prolonged survival (figure 6K–M), accompanied by a strong immune influx and increased levels of CD8+ T cells (figure 6N, O). This evidence concerns the gene CD8A and neoplasm.